[The evaluation of the use of DEAE-dextran in glycemic control in diabetic patients in pregnancy].
Thirty pregnant women with a pre-gestational history of type II diabetes or sugar intolerance and recruited during the second trimester of pregnancy, were administered DEAE-dextran (1 g x 3 times a day) in association with compensatory insulin therapy. Results of the end of trial tests showed amelioration of all of the parameters studied. The sugar curve after 120' from glucose load (100 g at fasting), showed a highly significant decrease at T90. Triglycerides T0 vs T90 gave p = 0.0001, probably due to improved body utilization of the insulin. DEAE-dextran was well tolerated and all of the patients enrolled at the beginning, completed the trial.
Valente
M
M
Università degli Studi di Roma La Sapienza, I Cattedra Clinica Ostetrica e Ginecologica.
Bazzoffi
R
R
Critelli
C
C
D'Angelo
R
R
Evangelista
E
E
Zichella
L
L
D001786:Blood Glucose / Q000032:analysis*; D003637:DEAE-Dextran / Q000008:administration & dosage*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000627:therapeutic use; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011254:Pregnancy in Diabetics / Q000097:blood / Q000188:drug therapy*
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D003637:DEAE-Dextran